Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19962094 | 0.96 | NR3C1 (0.31) | NR3C1PGRNR3C2 | |
| SCHEMBL19969256 | 0.94 | FOLH1 (0.33) | FOLH1NR3C1PGRNR3C2 | |
| SCHEMBL19962149 | 0.90 | ANPEP (0.31) | FOLH1ANPEPNR3C1PGRNR3C2 | |
| SCHEMBL19969224 | 0.90 | ANPEP (0.31) | FOLH1ANPEPNR3C1PGRNR3C2 | |
| SCHEMBL19962031 | 0.88 | FOLH1 (0.33) | FOLH1ANPEPCA12CA7CA9 | |
| SCHEMBL19962163 | 0.86 | NR3C1 (0.32) | ANPEPNR3C1PGRNR3C2 | |
| SCHEMBL19962029 | 0.86 | FOLH1 (0.34) | FOLH1ANPEPNR3C1PGRNR3C2 | |
| SCHEMBL19962136 | 0.85 | CA12 (0.35) | FOLH1ANPEPNR3C1PGRNR3C2 | |
| SCHEMBL19962074 | 0.85 | FOLH1 (0.33) | FOLH1ANPEP | |
| SCHEMBL19968983 | 0.84 | FOLH1 (0.33) | FOLH1ANPEPCA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072997-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2H, POLR2E | FOLH1 3511/4885ANPEP 2554/4885NR3C1 2931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.